停止拉米治疗后,病毒复发的慢性乙肝炎患者,拉米+阿德是一

StephenW

http://7thspace.com/headlines/390894/lamivudine_plus_adefovir_is_a_good_option_for_chronic_hepatitis_b_patients_with_viral_relapse_after_cessation_of_lamivudine_treatment.html
Lamivudine plus adefovir is a good option for chronic hepatitis B patients with viral relapse after cessation of lamivudine treatment


停止拉米夫定治疗后,病毒复发的慢性乙型肝炎患者,拉米夫定加阿德福韦是一个很好的选择，
Background and Aim:  Currently, there is no consensus on the retreatment recommendation of chronic hepatitis B (CHB) patients with viral rebound after cessation of treatment.   In the search of reasonable treatment, we compared the efficacy and safety of adefovir (ADV) plus LAM and LAM alone for the retreatment of patients with viral relapse but without genotypic resistance after cessation of LAM.

Methods: This is a prospective controlled study, and a total of 53 hepatitis B e antigen (HBeAg)-positive patients with viral rebound but without resistance were received either LAM plus ADV or LAM alone treatment.

Results: After 1-year treatment, More patients who received LAM plus ADV than those who received LAM alone had ALT normalization (84% versus 53.6%, P=0.018) or HBV DNA levels below 1000 copies/mL (80% versus 42.9%, P<0.006).

   Seven patients receiving LAM plus ADV had HBeAg seroconversion, as compared with 0 in patients receiving ALM alone (28% versus 0%, P=0.003).    During 1-year retreatment, five patients receiving LAM alone had virological breakthrough and all of them had LAM resistance strains (rtM204V/I), while no LAM- or AD- associated resistance strains were detected in patients receiving LAM plus ADV.

  All patients receiving LAM plus ADV were well tolerated, and no serious side effects were noted.

Conclusions: Patients treated with LAM plus ADV exhibited significantly greater virological, biochemical and serological responses compared with LAM alone.  These data suggest that combination of LAM plus ADV would be a good option for the retreatment of CHB patients with viral relapse after cessation of LAM.

Author: Zhao WangXiao-Ling WuWei-Zheng ZengHui XuYong ZhangJian-Ping QinMing-De Jiang
Credits/Source: Virology Journal 2011, 8:388




(6.合.彩).足球.篮球...各类投注开户下注

第一投注.现金网:招代理年薪10万以上:6668.cc

StephenW

谷歌翻译不是100％正确，仅供参考使用.

背景和目的：目前，还没有共识的复治的慢性乙型肝炎（CHB）患者停止治疗后病毒反弹建议。在寻找合理的治疗，我们比较了病毒复发的患者复治，但没有停止后的拉米基因型耐药阿德福韦（ADV），加上拉米和拉米单独的疗效和安全性。

方法：这是一项前瞻性的对照研究中，，一共有53型肝炎e抗原（HBeAg）阳性患者病毒反弹，但无阻力，共收到拉米加ADV或林单独治疗。

结果：经过1年的治疗，更多的患者比那些只收到拉米,拉米加ADV ALT正常化（84％比53.6％，P = 0.018）或HBV DNA水平低于1000拷贝/ ml（80％与42.9％ P <0.006）。

   7例患者接受拉米加ADV HBeAg血清学转换，患者接受单独的拉米（28％和0％，P = 0.003）0相比。在1年的复治，五名患者接受拉米单独病毒学突破，其中有拉米耐株（rtM204V/ I），而没有拉米或AD相关的耐药株，在患者接受拉米加ADV检测。

  所有患者接受拉米林加ADV耐受性良好，并没有严重的副作用。

结论：与拉米加ADV治疗的患者表现出显着更大的病毒学，生化和血清学反应，仅与
拉米相比。这些数据表明，拉米加ADV相结合，将是一个拉米停止后病毒复发的慢性乙型肝炎患者复治不错的选择。

作者：赵王小灵武威正增辉叙永县张健平秦明德江
积分/来源：病毒学杂志2011，8:388

682256

国人的文章，翻译成英文，再译成中文。
这就是翻来覆去。

StephenW

回复 682256 的帖子

正确的。你知道在哪里可以找到原来的文件吗？

买平安的

682256 发表于 2011-8-5 10:49
国人的文章，翻译成英文，再译成中文。
这就是翻来覆去。

其实就是抄袭，打着引用的名号。
抄袭抄袭也就算了，
中文和英语还都不过关,居然用google翻译。